| Bioactivity | CBS9106 (SL-801) is a reversible oral CRM1 inhibitor with CRM1 degrading and antitumor activities. CBS9106, inhibits CRM1-dependent nuclear export, causing arrest of the cell cycle and inducing apoptosis in a time- and dose-dependent manner for a broad spectrum of cancer cells[1]. |
| Target | CRM1 |
| Invitro | CBS9106 (0.01-10 μM; 72 hours) sensitizes cells to radiation and to suppress the growth of a variety of cancer cell lines. The estimated IC50 values range from 22.3 or 35.6 nM in multiple myeloma (MM).1S or RPMI-8226 cells and from 3 to 278 nM in 60 other human cancer cell lines[1].CBS9106 (1-400 nM; 24 hours) decreases CRM1 protein expression levels in a dose-dependent manner[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> Felezonexor 相关抗体: Cell Viability Assay[1] Cell Line: |
| In Vivo | CBS9106 (31.25-62.5 mg/kg for 5 times weekly, 125 mg/kg for 3 times weekly; p.o.; 2 weeks) significantly suppresses tumor growth at dose levels of 62.5 or 125 mg/kg in mice bearing human MM xenograft models[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: |
| CAS | 1076235-04-5 |
| Formula | C18H21ClF3N3O3 |
| Molar Mass | 419.83 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Sakakibara K, et al. CBS9106 is a novel reversible oral CRM1 inhibitor with CRM1 degrading activity. Blood. 2011 Oct 6;118(14):3922-31. |
Felezonexor
CAS: 1076235-04-5 F: C18H21ClF3N3O3 W: 419.83
CBS9106 (SL-801) is a reversible oral CRM1 inhibitor with CRM1 degrading and antitumor activities. CBS9106, inhibits CRM
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.